Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?


This Practice Point commentary discusses the findings and limitations of a randomized, double-blind study conducted by Parving and colleagues. The study evaluated the renoprotective effects of dual blockade of the renin–angiotensin–aldosterone system by adding aliskiren (an oral, direct renin inhibitor) or placebo to treatment with 100 mg daily losartan in… (More)
DOI: 10.1038/ncpneph0962


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics